PPTA Recognizes First Plasma Collection Centers Certified in Hungary
ANNAPOLIS, MD—The Plasma Protein Therapeutics Association (PPTA) has awarded Plazmaferezis Állomás Kft (PFÁ), a member operating within the Kedrion group of companies, with International Quality Plasma Program (IQPP) certification for its plasma collection centers in Hungary; two in Budapest and one in Debrecen. The three centers are the first in the country to become IQPP certified.
Certification is obtained via a rigorous inspection by an independent third party, and demonstrated compliance with voluntary standards that ensure the highest level of quality and safety of human source plasma.
Gabi Komlodi, the Managing Director, said, “Considering that the plasma collected ultimately serves the health and well-being of Hungarian patients, as part of Kedrion Group, we set the bar high and therefore wanted to measure up to the IQPP standards. Whatever we do, we want to do it right.”
People worldwide depend on lifesaving plasma protein therapies to treat bleeding and immune disorders, other diseases and injury. PFÁ’s mission has been to continuously improve with a focus on safety and quality from the donor to the patient.
Joshua Penrod, Vice President, PPTA Source said, “We congratulate Plazmaferezis Állomás Kft on obtaining this mark of distinction which demonstrates its commitment to plasma quality and safety.”
About Plazmaferezis Állomás Kft (“PFÁ”)
PFÁ is a member of Kedrion Group and is specialized in the collection of high-quality plasma which is processed into life-saving plasma-derived therapies at the group’s biopharmaceutical plants of Humán Bioplazma (Hungary) and Kedrion SpA (Italy). Owned by Humán Bioplazma, PFÁ is based in Gödöllő (Budapest, Hungary) and has three state-of-the-art collection centers, two in Budapest and one in Debrecen.
In Italy, Kedrion is the partner of the National Health Service for the achievement of nationwide self-sufficiency in plasma derivatives. With its headquarters in Italy, companies in Europe, Mexico and the United States, Kedrion distributes its plasma protein therapies in 90 countries worldwide. For more information about Kedrion, please visit www.kedrion.com
- Created on .